| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Greenwich Lifesciences, Inc. (GLSI) has 1 insider with recent SEC Form 4 filings, including 10 buys and 0 sells. GLSI is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 5.60M | $126.15M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 19, 2023 | Patel Snehal | CEO And CFO | Buy | 7,000 | $11.10 | $77,700.00 | +0.1% | |
| Apr 18, 2023 | Patel Snehal | CEO And CFO | Buy | 2,000 | $11.12 | $22,240.00 | - | |
| Apr 11, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 1,000 | $11.87 | $11,870.00 | +0.4% | |
| Apr 11, 2023 | Patel Snehal | CEO And CFO | Buy | 5,000 | $12.42 | $62,100.00 | - | |
| Mar 15, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $12.71 | $3,177.50 | - | |
| Mar 10, 2023 | Patel Snehal | CEO And CFO | Buy | 1,000 | $12.12 | $12,120.00 | - | |
| Feb 24, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $15.40 | $3,848.75 | - | |
| Feb 17, 2023 | Patel Snehal | CEO And CFO | Buy | 600 | $16.53 | $9,918.00 | - | |
| Feb 10, 2023 | Patel Snehal | CEO And CFO | Buy | 1,000 | $18.68 | $18,680.00 | - | |
| Feb 3, 2023 | Thompson Jaye | VP Clinical Reg Affairs | Buy | 250 | $20.84 | $5,210.00 | - |